In 2026, the pharmaceutical market is entering a period of significant transformation, as a number of the world’s most profitable drugs are set to lose patent protection. This wave of expiring exclusivity, often referred to in the industry as the “patent cliff,” may lead to a sharp decline in revenues for major pharmaceutical companies and a substantial redistribution of the market in favor of generic and biosimilar manufacturers.
According to industry analysts, starting from 2026, dozens of blockbuster drugs—medicinal products with annual sales exceeding $1 billion—will be at risk. Overall, these therapies span key areas of medicine, including oncology, cardiology, immunology, endocrinology, and chronic pain management. The loss of patent protection means that once the exclusivity period expires, generic and biosimilar products can enter the market, which traditionally leads to significant price reductions and a decline in profits for originator companies.
Among the most notable examples of drugs approaching loss of patent protection are key products of major pharmaceutical companies, including portfolios related to the treatment of diabetes, autoimmune diseases, and cardiovascular conditions. In many cases, these drugs account for a substantial share of companies’ total revenues, and their loss may therefore have a systemic impact on the financial stability of pharmaceutical giants.
The “patent cliff” phenomenon is not new to the industry; however, the scale of events in 2026 is particularly significant. The simultaneous expiration of patent protection for a large number of blockbuster drugs is creating a so-called “supercycle of loss of exclusivity,” which could affect hundreds of billions of dollars in potential sales in the coming years.
It is expected that large pharmaceutical companies, which are heavily dependent on a few key products, will be most affected. Following the loss of patent protection, such companies often face a sharp drop in revenue as the market rapidly shifts to more affordable alternatives. At the same time, this situation opens up significant opportunities for generic and biosimilar manufacturers to expand their market share.
Analysts also note that companies are already preparing for this wave of change by accelerating mergers and acquisitions, investing in biotechnology startups, and expediting the development of new products within their R&D portfolios. The aim of these strategies is to offset losses from the end of the lifecycle of existing blockbusters and to secure future revenue streams.
Thus, 2026 may become a pivotal turning point for the global pharmaceutical industry, when the balance of power between originator drug developers and generic manufacturers shifts significantly. The patent cliff not only creates risks for large corporations but also opens up new opportunities for competition and innovation in healthcare.
Founder of Research & Patent group Intectica, author of patent algorithms for solving problems in the pharmaceutical industry, patent attorney certified in all intellectual property objects (Patents, Design, TM), with education in chemistry and law, chief expert of the patent institution of Ukraine UKRPATENT (1997-2004). Member of international organizations, including ECTA, PTMG, UAM, lecturer and blogger.
